Gilead faces fresh Sovaldi challenge
20-05-2015
Daniel Fung / Shutterstock.com
China’s State Intellectual Property Office (SIPO) has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead; Sovaldi; Initiative for Medicines, Access & Knowledge; I-MAK; patent application; generic versions; hepatitis C